Assessing Diagnostics At Point-of-care for Tuberculosis
Sponsor: University of California, San Francisco • ClinicalTrials.gov ID: NCT05941052
Recruiting for Similar Conditions?
Sponsors are looking for patients like you. See if you qualify for compensated research studies.
Check Eligibility →Description
Every year, more than 3 million people with TB remain undiagnosed and 1 million die. Better diagnostics are essential to reducing the enormous burden of TB worldwide. The Assessing Diagnostics At Point-of-care for Tuberculosis (ADAPT) study seeks to reduce the burden of TB worldwide by evaluating faster, simpler, and less expensive TB triage and diagnostic tests.
Interventions
-
Tongue swab-based molecular assays
(Diagnostic test)
The investigators will evaluate semi-automated or automated molecular assays intended for use at near point of care or point of care.
Eligibility criteria
Conditions
Locations
- Zankli Research Center, Bingham University — Abuja, Nigeria
- De La Salle Medical and Health Sciences Institute — Dasmariñas, Philippines
- Centre for Infectious Disease Research in Zambia — Lusaka, Zambia
Partner with Nurenyx
Showcase your study to thousands of motivated patients matching your criteria.
Learn MoreOfficial Source
Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
View Official Record